XenoPort to Release First Quarter Financial Results on May 2, 2012
April 19 2012 - 1:00PM
Business Wire
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will
release its first quarter financial results on May 2, 2012 at
approximately 4:30 p.m. Eastern Time. The company will host a
conference call at 5:00 p.m. Eastern Time that same day. A replay
of the call will be available for one week following the event.
To access the conference call via the Internet, go to
www.XenoPort.com. Please join the call at least 15 minutes prior to
the start to ensure time for any software downloads that may be
required.
To access the live conference call via phone, dial
1-888-275-3514. International callers may access the live call by
dialing 706-679-1417. The reference number to enter the call is
73444304.
The replay of the conference call may be accessed that same day
after 8:00 p.m. Eastern Time, via the Internet, at
www.XenoPort.com, or via phone at 1-800-642-1687 for domestic
callers, or 706-645-9291 for international callers. The reference
number to enter the replay of the call is 73444304.
About XenoPort
XenoPort is a biopharmaceutical company focused on developing
and commercializing a portfolio of internally discovered product
candidates for the potential treatment of neurological disorders.
Horizant® (gabapentin enacarbil) Extended-Release Tablets is
XenoPort’s first FDA-approved product. GlaxoSmithKline holds
commercialization rights and certain development rights for
Horizant in the United States. Regnite® (gabapentin enacarbil)
Extended-Release Tablets is approved for the treatment of
moderate-to-severe primary restless legs syndrome in Japan.
Astellas Pharma Inc. holds all development and commercialization
rights for Regnite in Japan and five Asian countries. XenoPort
holds all other world-wide rights and has co-promotion and certain
development rights to gabapentin enacarbil in the United States.
XenoPort’s pipeline of product candidates includes potential
treatments for patients with postherpetic neuralgia, spasticity and
Parkinson’s disease.
To learn more about XenoPort, please visit the company Website
at www.XenoPort.com.
XENOPORT is a registered trademark of XenoPort, Inc.
Horizant is a registered trademark of GlaxoSmithKline.
Regnite is a registered trademark of Astellas Pharma Inc.
XNPT2F
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Sep 2023 to Sep 2024